Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 15/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.75 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1281851 | 0.91 | PIK3C2B (0.81) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| Gsk-2636771 SCHEMBL1281470 | 0.90 | PIK3C2B (0.89) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| SCHEMBL1281647 | 0.88 | PIK3C2B (0.83) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| SCHEMBL1282107 | 0.87 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| SCHEMBL1633027 | 0.86 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| Gsk-2636771 SCHEMBL1280998 | 0.86 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| Gsk-2636771 SCHEMBL29352801 | 0.86 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| Gsk-2636771 SCHEMBL29411881 | 0.86 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| Gsk-2636771 SCHEMBL16323314 | 0.85 | PIK3C2B (0.98) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG | |
| Gsk-2636771 SCHEMBL18860113 | 0.84 | PIK3C2B (0.83) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150342957-A1 | COMBINATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2019-08-22 | — | — | US | disclosed |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180263994-A1 | Benzimidazole Derivatives as PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2018-09-20 | — | — | US | disclosed |
| US-9872860-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170348329-A1 | Combination Drug Therapy | GLAXOSMITHKLINE LLC | 2017-12-07 | — | — | US | disclosed |
| US-20170112844-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2017-04-27 | — | — | US | disclosed |
| US-20160287610-A1 | Combination Drug Therapy | GlaxoSmithKline LLCC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160228446-A1 | Combination Drug Therapy | GlaxoSmithKline LLCC (US) | 2016-08-11 | — | — | US | disclosed |
| US-8865912-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014158467-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140142321-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | US | disclosed |
| US-8674090-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140018534-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-16 | — | — | US | disclosed |
| US-8541411-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130196990-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2013-08-01 | — | — | US | disclosed |
| US-20130197221-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-08-01 | — | — | US | disclosed |
| US-8435988-B2 | Benzimidazole derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112844-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20180263994-A1 | Benzimidazole Derivatives as PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20140018534-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20160287610-A1 | Combination Drug Therapy | CYP17A1, HSD17B3, HSD17B1 | PIK3C2B 45/4885PIK3CB 41/4885PIK3CD 37/4885 |
| US-20140142321-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20170348329-A1 | Combination Drug Therapy | CYP17A1, HSD17B3, HSD17B1 | PIK3C2B 45/4885PIK3CB 41/4885PIK3CD 37/4885 |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 3/4885 |
| US-20160228446-A1 | Combination Drug Therapy | AR, PIK3CA, PI4KB | PIK3C2B 17/4885PIK3CB 5/4885PIK3CD 4/4885 |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20130196990-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20150342957-A1 | COMBINATION | PAICS, CA6, CA5A | PIK3C2B 2640/4885PIK3CB 1535/4885PIK3CD 1381/4885 |
| US-20130197221-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.